Newsroom
Press Releases
Reviva Pharmaceuticals to Present at the 2023 BIO CEO and Investor Conference
Cupertino, Calif., Jan. 31, 2023 -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) ("Reviva" or the "Company"), a clinical-stage pharmaceutical company developing...
Reviva Pharmaceuticals Announces Letter to Shareholders
CUPERTINO, Calif., Jan. 04, 2023 -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) ("Reviva" or the "Company"), a clinical-stage pharmaceutical company developing...
Reviva Pharmaceuticals Announces Positive Safety Data from Drug-Drug Interaction Clinical Study of Brilaroxazine
- Topline data for pivotal Phase 3 RECOVER trial evaluating brilaroxazine for schizophrenia expected in mid-2023 - Brilaroxazine is a serotonin/dopamine modulator with a...
Articles & Videos
Reviva: The Potential Future Standard of Care for Schizophrenia
October 15, 2022 | Video Interview on Bloomberg TV featuring Laxminarayan Bhat, CEO Reviva Pharmaceuticals
New Schizophrenia Drug Shows Promise of Greater Success with Fewer Side Effects
May 5, 2022 | RealClear Health article by Laxminarayan Bhat, CEO Reviva Pharmaceuticals
Brilaroxazine for Schizophrenia and Other Neuropsychiatric Disorders
May 3, 2022 | KOL Webinar featuring Leslie Citrome, MD (New York Medical College), Larry Ereshefsky, PharmD (Apex Innovative Sciences), and Laxminarayan Bhat, CEO (Reviva Pharmaceuticals)
Unboxing Biotech Video Series
March 9, 2022 | Video series with Jahn Vandermosten of Zacks Research featuring Reviva CEO Laxminarayan Bhat
Engineered neuroreceptor-specificity set to deliver next-generation schizophrenia therapeutics
June 2021 | Nature Research article by Laxminarayan Bhat, CEO Reviva Pharmaceuticals
This page contains links to other third party sites. Clicking on a third party link will cause you to leave our website. The third party sites are not controlled by Reviva and we are not responsible for the content. Please see our Privacy Policy for more information regarding third party links and sites.